Latest studies
- RecruitingPhase I/II
A trial looking at different treatments for neuroblastoma which has come back after initial therapy
The BEACON2 trial is testing new combinations of cancer medicines for children and young people whose neuroblastoma has returned or worsened after initial treatment. The goal is to find out which drug combinations are safest and work best to control the disease and improve future care.
Relapsed NeuroblastomaFrance - CompletedPhase III
A randomized, open-label phase 3 study of amivantamab + FOLFIRI versus cetuximab/bevacizumab + FOLFIRI in participants with KRAS/NRAS and BRAF wildtype recurrent, unresectable or metastatic colorectal cancer who have received prior chemotherapy
This clinical trial is testing a new targeted drug, amivantamab, combined with chemotherapy for people with advanced bowel cancer. Researchers want to see if this combination works better at slowing cancer growth and helping people live longer than current standard targeted treatments after their first chemotherapy has stopped working.
Recurrent, unresectable or metastatic colorectal cancerFrance - RecruitingPhase I
A study of JNJ-95804306 for relapsed or refractory hematological malignancies
This early-stage clinical trial is testing a new medicine called JNJ-95804306 for adults with blood cancers that have returned or stopped responding to standard treatments. Doctors want to find safe doses and check how well the body handles the drug when given alone or with other cancer therapies.
Hematologic neoplasms, blood cancerFrance - CompletedPhase II
Testing new medicine for adults with Cystic Fibrosis who do not have access to the currently available CFTR-modulating drugs due to genetic mutations
This clinical trial tests a new three-in-one medicine for adults with cystic fibrosis who have rare genetic mutations. These patients cannot access currently approved treatments. Researchers are checking whether this daily combination of capsules can safely improve lung health after promising results in laboratory tests using patient cell samples.
Treatment of Cystic Fibrosis (CF) in patients with CFTR mutations who are responders in the organoid assayFrance - RecruitingPHASE2, PHASE3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
This study looks at a new medicine called ponsegromab for advanced pancreatic cancer that has spread, especially when patients have lost a lot of weight and feel very tired. It aims to see if adding ponsegromab to standard chemotherapy helps more than chemotherapy alone.
CachexiaMetastatic Pancreatic Ductal AdenocarcinomaFrance - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
This study looks at a new medicine called enicepatide for people who are overweight or have obesity and also have type 2 diabetes. We want to see if it helps with weight loss and if it's safe to use.
Obesity or OverweightType 2 Diabetes MellitusFrance - RecruitingPHASE3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
This study, called DLLEVATE, is looking at a new treatment, ZL-1310, for people with small cell lung cancer that has come back. It compares ZL-1310 to other standard treatments to see if it's safe and works well. You might be eligible if you're over 18 and have had previous treatments.
Small-cell Lung CancerFrance - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
This study is testing a new medicine, enicepatide, for people who are overweight or have obesity but do not have type 2 diabetes. It aims to see if the medicine helps with weight loss and if it's safe compared to a dummy medicine.
Obesity or OverweightFrance - RecruitingPhase II
Finding the best treatment for lung disease from infection with Mycobacterium abscessus
This clinical trial is testing different combinations of antibiotics to find the best way to treat lung infections caused by Mycobacterium abscessus. The goal is to discover which medicines work best to clear the bacteria while causing the fewest and least severe side effects for patients.
Mycobacterium abscessus pulmonary diseaseFrance - RecruitingPHASE3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
This study looks at a new drug, elritercept, for people with myelofibrosis and anaemia who are already taking ruxolitinib. It compares elritercept to a dummy drug (placebo) to see if it improves anaemia and other symptoms, and how safe it is.
MyelofibrosisAnemiaFrance - CompletedPhase I
A modular, multi-part, multi-arm, open-label, phase I/II study to evaluate the safety and tolerability of GRWD5769 alone and in combination with anticancer treatments in patients with solid malignancies
This early-stage clinical trial is testing a new cancer medicine called GRWD5769. It looks at how safe the drug is when taken alone or alongside another cancer drug, cemiplimab. It aims to help the body's immune system recognise and fight advanced solid tumours that have spread or cannot be cured.
Advanced or metastatic solid malignancyFrance - CompletedPhase II
A Phase II study to understand the safety and effects of inhaled SNG001, the study medication, in patients who are mechanically ventilated due to a respiratory viral infection in the lungs
This study tests an inhaled medicine called SNG001 for people in intensive care with severe chest infections caused by viruses like flu or COVID-19. Researchers want to see if breathing in this natural virus-fighting protein helps patients recover faster and spend less time on a breathing machine.
Respiratory viral infectionsFrance - CompletedPhase II
A two-part study to assess the effectiveness, safety, and blood levels of repeat doses of inhaled ETD001 in people with cystic fibrosis
This study looks at a new inhaled medicine called ETD001 for adults with cystic fibrosis. The treatment aims to loosen sticky lung mucus to help make breathing easier. Researchers want to see if the medicine is safe, well tolerated, and improves lung function when taken alongside usual daily care.
Cystic fibrosisFrance - RecruitingPHASE2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This study is testing a new medicine called belzutifan for certain types of advanced cancers, including rare adrenal gland, gut, and kidney cancers. We want to see how well it works and if it's safe for people aged 12 and over.
Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau DiseaseAdvanced Gastrointestinal Stromal TumorFrance - RecruitingPHASE2, PHASE3
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
This study is testing a new treatment called hu14.18K322A, given with chemotherapy, for children and young people with a type of cancer called high-risk neuroblastoma. It aims to see if this combination treatment is safe and effective in fighting the cancer.
High-Risk NeuroblastomaFrance - RecruitingPHASE3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
This study looks at a new treatment called AAA617 for men with early-stage prostate cancer that has spread a little (oligometastatic). It compares AAA617 to careful watching, to see if it can stop the cancer from growing and help men live better for longer.
Oligometastatic Prostate Cancer (OMPC)France - RecruitingPhase III
Tranexamic acid (and Desmopressin) for very early bleeds in the brain
This clinical trial tests whether an affordable medicine called tranexamic acid can stop bleeding in the brain after a stroke. Doctors want to see if giving this injection quickly in the emergency room helps people survive with less long-term disability, improving recovery and everyday life six months later.
Hyperacute primary intracerebral haemorrhage (stroke)France - RecruitingPhase III
Phase 3, randomised, double-blind, placebo- controlled, 3-arm study to investigate the safety and efficacy of efimosfermin alfa in participants with biopsy-confirmed F2- or F3-stage metabolic dysfunction-associated steatohepatitis (MASH) (ZENITH-1)
This clinical trial is testing a new injection called efimosfermin alfa for people with metabolic dysfunction-associated steatohepatitis (MASH), an inflamed fatty liver condition. Researchers want to see if monthly injections over four years can safely reduce liver fat, ease inflammation, and improve liver scarring compared to a dummy treatment.
Medical condition: Metabolic Dysfunction-Associated Steatohepatitis (MASH) Medical condition in lay language: Metabolic Fatty Liver Inflamation Therapeutic areas: Diseases [C] - Nutritional and Metabolic Diseases [C18]France - Completed
Evaluation of a dermocosmetic regimen for acne-prone skin in volunteers with mild, moderate or severe skin conditions
Acne is a common skin condition that affects confidence and well-being. This study tests whether a daily skincare routine using Eucerin products helps clear mild to severe spots. Researchers want to see how well these creams work over a year in people aged 12 to 50 across the UK and worldwide.
Subjects with acne-prone skin aged 12-50 years with Investigator's Global Assessment (IGA) grades 2-4, evaluating treatment of mild to severe acne vulgaris.France - RecruitingPhase III
A study of JNJ-78934804 in participants with moderately to severely active Crohn's disease
This clinical trial is testing a new combination medicine, JNJ-78934804, for moderate to severe Crohn’s disease. It combines two drugs into one injection to target gut inflammation. Researchers want to see if this two-in-one approach works better than a single medicine for people whose previous treatments have stopped working.
Crohn’s diseaseFrance - RecruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms.
This early-stage clinical trial is testing a new experimental medicine called INCB160058 for adults with myeloproliferative neoplasms (rare blood disorders). The main aim is to find out if the drug is safe, learn how the body handles it, and see what the best dose might be for future treatment.
Myeloproliferative NeoplasmsFrance - RecruitingTherapeutic exploratory (Phase II)
C1071003 - MAGNETISMM-3, An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One Proteasome Inhibitor, One Immunomodulatory Drug and One Anti-CD38 Antibody
This clinical trial is testing a new medicine called elranatamab for adults with multiple myeloma. It is designed for people whose cancer has returned or stopped responding after trying three standard types of treatment. The aim is to find out how well the drug works on its own.
Multiple myelomaFrance - RecruitingTherapeutic exploratory (Phase II)
A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.
This clinical trial is testing a new drug called petosemtamab combined with an established immunotherapy called pembrolizumab (Keytruda). It aims to find out if this combination is safe and effective at shrinking tumours in adults diagnosed with non-small cell lung cancer.
Non Small Cell Lung CancerFrance - CompletedPhase III
MyeChild 01: Treating children with acute myeloid leukaemia
MyeChild 01 is a clinical trial for children and young people with acute myeloid leukaemia (AML). It tests whether adding a targeted drug called gemtuzumab ozogamicin to standard chemotherapy helps clear leukaemia cells more effectively and safely. It also looks at the best chemotherapy combinations before a stem cell transplant.
Acute myeloid leukaemiaFrance - AuthorisedTherapeutic exploratory (Phase II)
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
This clinical trial is testing an experimental medicine called TAK-360 for adults with narcolepsy type 1. Researchers want to see if the medicine is safe and helps reduce daytime sleepiness and sudden muscle weakness (cataplexy). Participants will receive either the study medicine or a dummy pill for comparison.
Narcolepsy with Cataplexy (NT1)France - AuthorisedTherapeutic use (Phase IV)
Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program
This study monitors the long-term safety of a gene therapy called Libmeldy in adults treated for metachromatic leukodystrophy (MLD). Doctors collect blood and tissue samples to check for very rare risks, such as abnormal cell growth or cancer, helping to ensure the treatment remains safe over time.
Metachromatic leukodystrophyFrance - AuthorisedPhase I and Phase II (Integrated)- Other
Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular carcinoma treated with selective internal radiotherapy
This study is testing a specialised scan called a dynamic PET-CT in people with liver cancer. Researchers want to see if this detailed scan can predict whether a radiation treatment called SIRT will successfully shrink the tumour six months later, helping doctors plan better treatments in the future.
HCC – Hepatocellular CarcinomaFrance - Completed
The SENSE-Cog Randomised Controlled Trial (RCT): Comparing individualised sensory intervention to standard care to improve quality of life in people with dementia and their companions
This trial looks at whether personalised support for hearing and sight loss improves daily life for people with dementia and their carers. Half of participants receive free hearing aids or glasses with home visits from a therapist, while the other half receive standard care and advice.
DementiaFrance - AuthorisedTherapeutic use (Phase IV)
ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment
This study looks at a specialised scan called a PSMA PET scan. Researchers want to find out how well this scan detects if prostate cancer has returned one year after focused ultrasound treatment (HIFU). The scan uses a gentle tracking dye to help doctors spot any lingering cancer cells early.
prostate cancerFrance - AuthorisedTherapeutic exploratory (Phase II)
Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA
Heavy drinking can damage brain cells and lower vitamin B1 (thiamine) levels. This study tests whether taking daily thiamine supplements for two weeks protects brain cells in adults with alcohol use disorder. Doctors measure special proteins in blood samples to see if the vitamin helps reduce nerve damage.
AlcoholismFrance - AuthorisedPhase I and Phase II (Integrated)- First administration to humans
Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome
This early clinical trial is testing an experimental medicine called ION337 for people with Dravet syndrome. Researchers want to find out if the drug is safe, how the body handles it, and whether it can help reduce the number of major seizures patients experience.
Dravet SyndromeFrance - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
This clinical trial looks at whether a targeted medicine called taletrectinib can stop lung cancer from returning. It is for adults who have had surgery to completely remove non-small cell lung cancer with a specific gene change known as ROS1. Participants take either taletrectinib capsules or dummy capsules.
Non Small Cell Lung Cancer (NSCLC)France - AuthorisedTherapeutic confirmatory (Phase III)
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
This study tests an inhaled dry powder medicine called treprostinil palmitil for adults with high blood pressure in the lungs linked to lung scarring. The trial lasts up to two years to see if the medicine is safe and helps improve breathing, walking ability, and overall quality of life.
Pulmonary Hypertension Associated with Interstitial Lung DiseaseFrance - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This study tests a new medicine called MTX-474 for adults with diffuse cutaneous systemic sclerosis. This rare condition causes skin thickening and hardening across the body. Researchers want to see if MTX-474 is safe and if it helps soften the skin over 24 weeks compared to a dummy treatment.
Diffuse Cutaneous Systemic Sclerosis (dcSSc)France - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease
This study tests a new medicine called surovatamig for adults with kidney disease caused by the immune system. Doctors want to see if it is safe and can lower protein leaking into the urine, which helps protect kidney function. Everyone in the trial receives the active study medicine.
Antibody-mediated Kidney DiseaseFrance - AuthorisedTherapeutic exploratory (Phase II)
Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial (OBLUMEN)
This clinical trial looks at whether a medicine called obinutuzumab can help adults with lupus that affects their kidneys. Researchers want to see if this treatment can reduce kidney swelling, improve kidney health over one year, and allow people to cut down on their daily steroid tablets.
systemic lupus erythematosus pure membranous nephropathyFrance - AuthorisedTherapeutic confirmatory (Phase III)
PROPHY-SEIN - Evaluation of the effect of antibiotic prophylaxis during lumpectomy for breast cancer: prospective randomised double-blind noninferiority study of placebo vs cefazolin
This study looks at whether women having breast cancer surgery really need antibiotics to prevent wound infections. Researchers are comparing a standard antibiotic called cefazolin with a harmless salt-water dummy drip (placebo) to see if skipping antibiotics is safe, helping to reduce unnecessary medication use and potential side effects.
Breast CancerFrance - RecruitingTherapeutic exploratory (Phase II)
A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
This clinical trial looks at whether combining two medicines, eplontersen and ALXN2220, is safe and effective for adults with a heart condition called ATTR-CM. Researchers want to find out if using both treatments together helps improve breathing, exercise fitness, and overall heart health better than taking eplontersen with a dummy drug.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)France - AuthorisedTherapeutic exploratory (Phase II)
DOXYCYCLINE PENETRATION INTO BONE AND JOINT.
This study looks at how well a common antibiotic, doxycycline, reaches the hip bone and joint fluid. It is for adults having planned hip replacement surgery for severe hip arthritis. Researchers want to see if this medicine gets into the joint well enough to help treat or prevent bone infections.
Patients requiring total hip arthroplasty for coxofemoral osteoarthritisFrance - AuthorisedTherapeutic confirmatory (Phase III)
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam
This phase 3 study tests an investigational medicine called salanersen (BIIB115) for people aged 15 to 60 with spinal muscular atrophy (SMA). Researchers want to see if it helps improve physical movement, arm strength, and walking ability over time in people new to treatment or previously treated with risdiplam.
Spinal Muscular AtrophyFrance - AuthorisedTherapeutic exploratory (Phase II)
DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer
This trial looks at early triple-negative breast cancer. Researchers want to find out if 12 weeks of combined chemotherapy and immunotherapy before surgery can completely clear the tumour. If successful, this shorter treatment could help patients avoid heavier chemotherapy drugs, reducing difficult side effects while keeping care effective.
triple‑negative breast cancerFrance - AuthorisedTherapeutic exploratory (Phase II)
Evaluation of the effect of botulinum toxin on refractory upper limb rest tremor in parkinsonian patients, double-blind, placebo-controlled cross-over study : TOX PARK
This clinical trial is testing whether injections of botulinum toxin can help calm hand and arm tremors in people with Parkinson's disease. Researchers want to see if this treatment helps when standard medicines have not worked well enough, while checking that it is safe and improves daily life.
parkinson diseaseFrance - AuthorisedPhase III and phase IV (Integrated)
4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome
This study tests whether a medicine called elamipretide can help men with Barth syndrome. Researchers want to see if daily injections under the skin can improve physical strength, walking ability, and day-to-day energy over 72 weeks, compared to an inactive dummy injection known as a placebo.
Barth SyndromeFrance - RecruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3
This study tests a new experimental drug, S233107, for adults living with spinocerebellar ataxia type 3 (SCA3). Because this is the first time the medicine is tested in people, researchers want to see if it is safe, how well the body handles it, and how it moves through spinal fluid.
Spinocerebellar ataxia type 3France - AuthorisedTherapeutic exploratory (Phase II)
A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.
This study looks at a new medicine called PTI5803 for people with difficult-to-treat epilepsy caused by focal cortical dysplasia. Researchers want to find out if taking this add-on treatment over a longer period is safe, well-tolerated, and helpful for reducing seizures and improving daily quality of life.
Drug resistant focal epilepsy related to focal cortical dysplasiaFrance - AuthorisedTherapeutic exploratory (Phase II)
VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study
The VIP-1 study looks at whether a common blood pressure medicine, verapamil, can protect insulin-making cells in people at high risk of developing type 1 diabetes. Researchers want to see if taking this daily pill for 48 weeks helps keep blood sugar levels steady and delays full diabetes.
People with stage 1 or stage 2 T1D between the ages of 7 and 45France - AuthorisedPhase III and phase IV (Integrated)
BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection
This study looks at whether personalised antibiotic doses help critically ill patients in intensive care recover faster from severe infections like sepsis. Doctors will test blood levels and use computer models to tailor standard antibiotic amounts to each person, aiming to clear infections sooner and reduce time spent in the ICU.
sepsisFrance - AuthorisedTherapeutic use (Phase IV)
HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial
This study looks at adults who have had an organ transplant and developed an infection called cytomegalovirus (CMV). Researchers want to see how different anti-rejection medicines, including everolimus and mycophenolic acid, affect virus levels in the blood over three weeks, helping doctors improve care for transplant patients.
Cytomegalovirus infection in solid-organ transplant recipients.France - AuthorisedTherapeutic confirmatory (Phase III)
Topical Clobetasol Propionate for Inflammatory Hand osteoarthritis: A randomized trial versus placebo.(PROCLAME)
This study tests whether a skin cream called clobetasol propionate can reduce pain and swelling in people with hand osteoarthritis. Researchers are comparing this medicated steroid cream against a dummy cream with no active medicine over four weeks to see if it improves comfort and daily hand movement.
Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.France - AuthorisedTherapeutic confirmatory (Phase III)
A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)
This phase III clinical trial tests a medicine called atrasentan in children and teenagers aged 2 to 17 who have IgA nephropathy, a kidney condition. Researchers want to see if the drug safely lowers the amount of protein leaking into the urine, which helps protect kidney health.
Primary IgANFrance